FDA approves Revolution Medicines' Rasonque for pancreatic cancer treatment

The US FDA has approved Rasonque, a new oral medication developed by Revolution Medicines for the treatment of pancreatic cancer. While the drug is not curative, it represents a new therapeutic option for a highly lethal malignancy, though clinical efficacy data and long-term patient outcomes remain to be fully integrated into standard care protocols.